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Abstract: Renal function impairment in lung cancer patients with bone metastases was 
investigated, as this can limit the application of bisphosphonates representing the gold 
standard in the management of such cases. Clinicopathological data of 570 lung cancer 
patients were retrospectively analysed for changes in renal function parameters. Co-
morbidities included hypertension (50%), COPD (33%) and diabetes mellitus (15%). Statistical 
analysis was performed with Fisher’s exact tests and a Cox proportional hazards model. In 
patients suffering from hypertension, both median serum creatinine and blood urea 
nitrogen (BUN) were higher (81.9 versus 75.8 µmol/l, p<0.001 and 6.0 versus 5.7 mmol/l, 
p=0.005, respectively). Such a difference could not be observed in patients with diabetes. In 
COPD patients, only serum creatinine was higher (81.1 versus 77.3 µmol/l, p=0.004). In the 
whole cohort, we found that while at the time of lung cancer diagnosis the ratio of patients 
in the pathological range (PRR) was 8.67% for serum creatinine (median: 75 µmol/l) and 
14.16% for BUN (median: 5.4 mmol/l), at the time of bone metastasis the PRR for serum 
creatinine increased to 16.11% (median: 77.0 µmol/l) and for BUN to 24.07% (median: 6.0 
mmol/l), which is a significant increase for both parameters (p<0.001). For the whole cohort, 
the last laboratory results showed a 26.37% PRR for serum creatinine and 45.66% PRR for 
BUN (significant increase for both, p<0.001). Multivariate analysis revealed that patients 
with hypertension had a higher chance for switching to the pathological range sooner 
(p=0.033, HR: 1.372, CI: 1.025-1.835). Also, the appearance of the bone metastasis 
correlated with an acceleration of the onset of such a switch (p<0.001, HR: 2.655, CI: 1.581-
4.456). Our results suggest that renal function is impaired in a significant proportion of lung 
cancer patients and highlight the importance of non-nephrotoxic drug in the management of 
bone metastases. 
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Abbreviations: 
ADC: adenocarcinoma 
BS: survival after bone metastasis 
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COPD: chronic obstructive pulmonary disease 
CT: computed tomography 
EGFR-TKI: epidermal growth factor receptor – tyrosine kinase inhibitor 
FR: failure rate; ratio of new pathological cases for a time period 
MRI: magnetic resonance imaging 
NSCLC: non-small cell lung cancer 
OS: overall survival 
PET: positron emission tomography 
PRR: ratio of cases with laboratory data in the pathological range 
SCC: squamous cell carcinoma 
SCLC: small cell lung cancer 
 
Lung cancer is the leading cause of cancer mortality worldwide. 25-30% of lung cancer 
patients present with skeletal involvement at the time of diagnosis of primary tumour and 
another 10% of patients develop bone metastasis during disease progression [1]. As lung 
cancer is the most common cancer in the world with 1.8 million new cases diagnosed in 
2012, the expected incidence of lung cancer with bone metastasis is around 600,000-
700,000 worldwide [2].  
Bone metastases in lung cancer are associated with significant morbidity, loss of functional 
independence and reduction in quality of life [3]. Patients who developed a skeletal-related 
event (SRE) have a prognosis worse than patients without SRE: this occurrence increases the 
risk of death by 20% to 40% [4]. Prevention of SREs in lung cancer could have an important 
economic impact demonstrated in a study of Delea et al. as the increased healthcare cost in 
patients with SREs was estimated at approximately 27,982 USD, while the cost of treatment 
of SREs was 9480 USD per patient [5,6]. 
Bisphosphonates, specific inhibitors of osteoclasts, have an important role in the treatment 
of tumour-induced hypercalcaemia and in decreasing the frequency of SREs. Recently, it has 
been proposed that these agents may prevent skeletal metastases [7]. Among 
bisphosphonates, zoledronic acid is the most commonly used drug to prevent, reduce the 
incidence and delay the onset of SREs. However, avoidance of use of these drugs is 
recommended in patients with renal impairment, and consideration should be given to using 
drugs that do not require dose adjustment based on glomerular filtration rate [8,9,10].  
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The relationship of renal function and cancer has been described in a number of 
publications, as Malyszko has summarized in a recent review with 169 references [11]. This 
publication gives an excellent overview of chronic kidney disease in different malignancies, 
however, it refers only to a single article about lung cancer, in which renal insufficiency and 
anti-cancer medication were analysed in 445 patients [12]. They found that 14.4% of 
patients had a serum creatinine level >110 µmol/L, however, when they were assessed using 
the Cockcroft–Gault formula, 62.1% had abnormal renal function. 
Lung cancer mainly occurs in elderly people as about 2 out of 3 people diagnosed with lung 
cancer are 65 years or older [13]. It has been estimated that active smoking is responsible for 
close to 90% of lung cancer cases. Both the advanced age, as well as the cardiovascular 
disorders caused by smoking increase the risk of renal impairment. In addition, platinum-
based chemotherapy used as first line treatment in lung cancer is also nephrotoxic. Despite 
all this, we have little information about the renal function of either lung cancer patients or 
lung cancer patients with bone metastases. Kutluk et al. studied 298 stage IV non-small cell 
lung cancer patients and found that renal function fell below commonly used thresholds for 
cisplatin and for pemetrexed in fewer than a quarter of patients [14]. They, however, did not 
analyse the changes in renal function during the progression of lung cancer, nor stratified 
patients according to the site of distant metastasis.  
The aim of the present study was to retrospectively analyse the clinicopathological data of 
lung cancer patients with bone metastasis to estimate the proportion of patients in whom 
bisphosphonate treatment is hampered by decreased renal function. Our main goal was to 
determine the influencing factors of the renal function deterioration, including co-
morbidities, previously administered platinum-based cytotoxic chemotherapy, and the 
malignant process itself. 
 
Materials and methods 
Patient data 
We analysed the clinicopathological data of 570 lung cancer patients with bone metastasis, 
including unselected 405 consecutive patients with proven bone metastasis and 165 
selected patients with previous surgical resection of the primary tumour. Ethical permission 
for the study was granted by the Scientific and Research Ethics Committee of the Medical 
Research Council (ETT-TUKEB No 510/2013 and No 109/2016).  
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Bone metastasis, treatments and co-morbidities 
At the time of lung cancer diagnosis, 196 patients suffered from bone metastasis, and others 
developed bone involvement during disease progression.  
The diagnosis of bone metastasis was established in all cases by imaging procedures, 
including Technetium-99m (99m Tc) bone scintigraphy, CT scanning, magnetic resonance 
imaging (MRI), fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning or 
conventional radiography.  
Beside surgical resection of the primary tumor, other types of active oncotherapy, including 
chemotherapy, molecular targeted treatment and bisphosphonate treatment were also 
analysed. 
The most important co-morbidities that might influence the renal function of patients, 
including diabetes mellitus, hypertension and COPD were also recorded. The clinical, 
histopathological and radiological data for all cases are summarized in Table 1. 
 
Investigated renal function parameters 
We have recorded the level of serum creatinine and BUN at the time of both the diagnosis of 
lung cancer and the diagnosis of bone metastasis. Ranges between 36-106 µmol/l for serum 
creatinine and 1.7-8.3 mmol/l for BUN were considered normal. Patients with postoperative 
complications, such as acute infection or sepsis which could have influenced the laboratory 
results were excluded from this analysis. Regarding the creatinine and BUN levels, the results 
before death or the last available laboratory results were also recorded.   
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 software (GraphPad Software 
Inc., San Diego, USA) for Mann-Whitney U test and Spearman non-parametric correlation, 
while SPSS 17.0 software (SPSS Inc., Chicago, Ill, USA) was used for multiple regression 
survival analysis. We confronted the other variables with Fisher’s exact tests. A Cox 
proportional hazard model was applied (R survival package) for the analysis of the switching 
time to the pathological range. We considered p<0.05 as a statistically significant difference.  
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Results 
Time to bone metastasis, overall survival (OS) and survival from bone metastasis (BS) 
The median time to bone metastasis was 4.20 months (0-150 months). There were 
differences between patients with surgically resected primary tumour and patients without 
surgery in favour of the operated group (61.0 versus 4.4 weeks, p<0.001, Mann-Whitney).  
The median OS was 13.7 months. Primary tumour resection, performed in 189 patients, 
favourably influenced OS (10.1 versus 29.8 months, p<0.001, Mann-Whitney). 
Chemotherapy applied only before bone metastasis increased OS (17.4 versus 13.5 months, 
p=0.025, Mann-Whitney), however, it did not influence BS. Chemotherapy applied only after 
skeletal involvement resulted in better BS (9.4 versus 3.2 months, p<0.001, Mann-Whitney). 
In patients who received chemotherapy both before and after bone metastasis, no 
significant OS benefit could be demonstrated (p=0.27, Mann-Whitney), but BS was longer 
(7.4 versus 3.9 months, p<0.001, Mann-Whitney).   
Bisphosphonate therapy after bone metastasis diagnosis resulted only in a tendency of 
better OS (14.8 versus 9.2 months, p=0.074, Mann-Whitney). BS, however, was significantly 
better in these patients (7.5 versus 2.1 months, p<0.001, Mann-Whitney). 
Serum creatinine level at the time of lung cancer diagnosis did not have a clear relation with 
OS, however, in case of increased BUN shorter OS could be observed (7.4 versus 14.5 
months, p=0.044, Mann-Whitney). Similarly, serum creatinine level at the time of bone 
metastasis diagnosis did not have a connection with BS, however, a tendency between 
increased BUN and shorter BS could be demonstrated (6.8 versus 3.0 months, p<0.001, 
Mann-Whitney). 
 
Renal function parameters at the time of lung cancer diagnosis 
There was a correlation between older age and higher renal function parameters at the time 
of lung cancer diagnosis (p<0.001, R=0.225 Spearman) for both parameters. In cases with 
abnormal creatinine level, the mean age was 64.4 versus 61.8 years in the normal range 
(p=0.060, Mann-Whitney). Similarly, in cases with abnormal BUN level, the mean age was 
67.1 years, whereas in the normal range, it was 61.2 years (p<0.001, Mann-Whitney).   
Renal function parameters were higher in men at the time of lung cancer diagnosis (median 
creatinine: 83.4 versus 71.6 µmol/l, p<0.001 and median BUN: 6.1 versus 5.5 mmol/l, 
p<0.001, respectively, Mann-Whitney). Increased serum creatinine was observed in 10.2% of 
men and in 5.1% of women, whereas BUN was increased in 15.9% of men and 8.9% of 
women.  
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Interestingly, we found no correlation between smoking and renal function parameter levels 
either in the never/ever smoker, or in the never/ex-/current smoker categories. 
To investigate the relationship between co-morbidities and renal function parameters at the 
time of lung cancer diagnosis, the ratio of patients with parameters in the pathological range 
(PRR = “pathological range ratio”) for each co-morbidity group and renal function parameter 
was calculated (Table 2). Table 2 indicates that using 8 different co-morbidity groups for 
statistical analysis is impractical due to the relatively small number of cases in some of them.  
To determine which co-morbidities seem to influence renal function parameters the most, 
median values were compared for cases with and without a single co-morbidity. In patients 
suffering from hypertension, both median serum creatinine and BUN were higher (81.9 
versus 75.8 µmol/l, p<0.001 and 6.0 versus 5.7 mmol/l, p=0.005, respectively, Mann-
Whitney). Such a difference could not be observed in patients with diabetes. In COPD 
patients, only serum creatinine was higher (81.1 versus 77.3 µmol/l, p=0.004, Mann-
Whitney).  
As the presence of hypertension seems to separate patients with high versus low renal 
function parameters the most efficiently out of all investigated co-morbidities, , further 
analyses were performed using two co-morbidity groups, defined as patients who suffer 
from hypertension and patients who do not. For different features of the analysis, see Fig. 1. 
In the case of serum creatinine levels, patients without hypertension have a lower PRR at 
diagnosis than patients with hypertension (Fig. 1A). This is supported by a borderline 
significant p-value of 0.053 (Fisher's exact; Supplementary file 1, Table S1.1). The same 
tendency for BUN levels could be observed (Fig. 1D) but not verified with a significance test. 
At this point, neither chemotherapy nor bisphosphonate treatment should have any effect 
on PRR, as neither was administered to any of the patients at the time of lung cancer 
diagnosis. Thus, any differences that could be seen in the initial PRR values for different 
treatment groups would be due to the fact that during treatment selection the values of 
laboratory parameters are taken into account. 
 
Changes in renal function parameters from diagnosis to bone metastasis 
We define the failure rate (FR) of a group for a given time period as the ratio of patients who 
have renal function parameters in the normal range in the beginning of the time period, but 
who switch to the pathological range by the end of it and the size of the group. In other 
words, FR is the ratio of new pathological cases in the group.  
In the whole cohort, we found that while at the time of lung cancer diagnosis the PRR was 
8.67% for serum creatinine (median: 75 µmol/l) and 14.16% for BUN (median: 5.4 mmol/l), 
at the time of the bone metastasis the PRR for serum creatinine increased to a 16.11% value 
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(median: 77.0 µmol/l) and for BUN to 24.07% (median: 6.0 mmol/l). This is a significant 
increase in median values for both parameters (p<0.001, Mann-Whitney). 
Comparing patients with and without hypertension (Fig. 1B and 1E) resulted in significantly 
higher FRs for both serum creatinine and BUN in the group of patients with hypertension 
(p=0.010 and p=0.005, respectively, Fisher’s exact, Supplementary file 1, Table S1.2), 
meaning that patients who suffer from hypertension are significantly more likely to switch to 
the pathological range from an initially normal value by the time of the bone metastasis than 
patients without hypertension. To assess the relationship of chemotherapy before bone 
metastasis and FR, co-morbidity groups of hypertension versus no hypertension were further 
grouped into treatment groups of chemotherapy versus no chemotherapy. We found that in 
both co-morbidity groups, patients who received chemotherapy before the bone metastasis 
had higher FRs than patients who did not, thus were more likely to switch to the pathological 
range for both serum creatinine and BUN. A significant difference was only established in the 
case of "no hypertension + chemotherapy versus no hypertension + no chemotherapy" 
comparison for serum creatinine (p=0.006, Fisher’s exact), but strong tendencies to this 
effect could be observed in all other comparisons (Supplementary file 1, Table S1.3).  
 
Changes in renal function parameters from bone metastasis to the last laboratory results 
For the whole cohort, the last laboratory results showed a 26.37% PRR for serum creatinine 
(median: 83 µmol/l) and 45.66% PRR for BUN (median: 7.60 mmol/l), which is a significant 
increase from the median values measured at the bone metastasis (p<0.001 for both, Mann-
Whitney). 
After the bone metastasis, FRs of patients with and without hypertension are not 
significantly different from each other (Fig. 1C and 1F), but significantly higher than before 
the bone metastasis (Fig. 1B and 1D) for patients without hypertension for both serum 
creatinine and BUN (p=0.010 and p<0.001, respectively, Fisher’s exact test) and BUN for 
patients with hypertension (p=0.025, Fisher’s exact test; Supplementary file 1, Table S1.4).  
After bone metastasis, the majority of the patients received bisphosphonate treatment, 
which can explain the significantly increased FRs in this group (Supplementary file 1, Table 
S1.5). In patients who did not receive bisphosphonate treatment, FR was also slightly 
increased in most cases, and a significant increment was found in patients with hypertension 
for serum creatinine (p=0.042, Fisher’s exact test; Supplementary file 1, Table S1.5). The 
latter result suggests that the deterioration of serum creatinine levels after the bone 
metastasis is accelerated but not solely due to the effects of bisphosphonate treatment. 
We also found that chemotherapy after the bone metastasis is accompanied by a significant 
increase in FRs (Supplementary file 1, Table S1.6).  
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Multivariate model for the time of switching to the pathological range 
To find significant prognostic factors of the time it takes for a patient with normal renal 
function parameters to switch to the pathological range, a multivariate Cox-model was built 
using actual times instead of the above-described abstract time steps (at lung cancer 
diagnosis, at bone metastasis, last laboratory). The details of model building and the 
approach for model selection can be found in Supplementary file 2. 
The most interesting results for serum creatinine were that patients with hypertension were 
more likely to switch to the pathological range sooner (p=0.020, HR: 1.639, CI: 1.081-2.485) 
and switches after the bone metastasis occurred significantly sooner than before the bone 
metastasis (p<0.001, HR: 3.022, CI: 1.591-5.740), suggesting that the appearance of the bone 
metastasis itself accelerates the increase in serum creatinine levels. Other relevant factors 
are presented in Supplementary file 2. 
Similarly for BUN, patients with hypertension have a higher chance for switching to the 
pathological range sooner (p=0.033, HR: 1.372, CI: 1.025-1.835). Also, the appearance of the 
bone metastasis seemed to accelerate the onset of such a switch (p<0.001, HR: 2.655, CI: 
1.581-4.456).  Other relevant factors are presented in Supplementary file 2. 
To more clearly illustrate that the appearance of bone metastasis has a significant effect on 
renal function independently on the treatment received, Kaplan-Meier curves were plotted 
for patients who did not receive either bisphosphonate treatment or chemotherapy for their 
bone metastasis (Fig. 2). 
 
Discussion 
We analysed data of lung cancer patients in a case-by-case manner in order to avoid bias of 
population-based data. Our results highlight the importance of co-morbidities in lung cancer 
patients with bone metastasis as we found that in the late phase of the disease, 27% of 
patients had abnormal creatinine level, and 46% of patients had abnormal BUN level due to 
co-morbidities affecting the kidney, applied oncotherapies and seemingly the appearance of 
bone metastasis. Apart from EGFR-TKI treatment in patients with advanced stage lung 
adenocarcinoma with sensitizing EGFR mutation, which is a minority of lung cancer patients, 
platinum-based chemotherapy is the gold standard of oncotherapy in surgically unresectable 
cases [15]. Application of this treatment, however, is often limited by poor kidney function 
[16]. Moreover, in case of bone metastasis, which occurs in up to 40% of lung cancer cases, 
the necessary bisphosphonate treatment is also limited by impaired renal function [17]. 
Approximately 90% of lung cancer cases are attributed to cigarette smoking, which is also 
responsible for other morbidities, such as hypertension and diabetes both of which have 
been known to contribute to the deterioration of renal function. Our data are in line with 
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the findings of Edwards et al., who reported that lung cancer had the highest prevalence of 
co-morbidities compared with colorectal, breast or prostate cancers [18].  
At the time of lung cancer diagnosis, we found impaired kidney function determined by 
abnormal creatinine level in 8% of patients. This proportion is somewhat higher than that 
found in a recent large study of 5683 lung cancer patients, in which renal disease was 
recorded in 5.7% of patients [19]. This might be explained by the fact that we investigated 
lung cancer patients with bone metastasis which was already present at the time of 
diagnosis in 40% of the patients. Bone metastasis is known to impair kidney function as it 
has already been demonstrated in a large cohort of 15,623 cancer patients including 3,839 
patients with bone metastasis [20]. This is in line with our results which showed that the 
appearance of bone metastasis has a significant effect on renal function and was 
independent on the bisphosphonate treatment and/or chemotherapy received. Our study 
analysed renal function not only at the time of lung cancer diagnosis but also at the time of 
bone metastasis diagnosis as well as used the last available laboratory data. This approach 
gave us the possibility to demonstrate the deterioration of renal function in a longitudinal 
way, as it has never been studied before. Furthermore, to the best of our knowledge, our 
study group is the largest and most homogeneous cohort of lung cancer patients regarding 
the site of distant metastasis with such kidney function results.  
The weakness of our study, however, is that we analysed serum creatinine and BUN used in 
the routine clinical practice instead of glomerular filtration rate. Estimated glomerular 
filtration rate was found to be a more sensitive indicator of renal impairment; therefore, our 
results certainly underestimate the proportion of patients with decreased kidney function 
[12,20]. In this light, our results further raise awareness that in this patient population, 
application of nephrotoxic drugs may frequently require dose adjustment or discontinuation.   
Bisphosphonates are potent drugs used to inhibit osteoclast-mediated bone resorption and 
prevent SREs. In pre-clinical studies on human cancer cells lines derived from both SCLC and 
NSCLC, they seem to inhibit proliferation, induce apoptosis and have an immunomodulatory 
effect and active anti-tumour immune response [21-23]. Furthermore, recently, adjuvant 
bisphosphonate therapy was found to reduce the rate of bone metastasis development and 
improve breast cancer survival in women who were postmenopausal when treatment began 
[24]. Because of this, our findings highlight the importance of renal function control before 
bisphosphonate treatment not only in lung cancer patients with bone metastasis but also in 
breast cancer patients in whom bisphosphonates are intended to be used for prevention of 
distant metastases.    
In summary, our results demonstrate that renal function is impaired in a significant 
proportion of lung cancer patients and hypertension is an important co-morbidity, which 
facilitates its development. These findings highlight the importance of considering the 
application of non-nephrotoxic drugs in the management of lung cancer patients with bone 
metastases and impaired renal function [25].  
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Tables 
 Number Age (years) 
Patients 570 61.95 (33-89) 
     Male 335 62.04 (37-89) 
     Female 235 61.82 (33-89) 
Histology   
     Adenocarcinoma 321  
     Squamous cell carcinoma 129  
     Small cell lung cancer 61  
     Anaplastic carcinoma  41  
     Adenosquamous carcinoma 11  
     Large cell carcinoma 7  
Stages at the time of lung cancer diagnosis 
(available in 555 cases) 
  
     I 67  
     II 52  
     IIIA 97  
     IIIB 46  
     IV 293  
          Bone metastasis 196  
Bone metastasis total: 631∗  
     99m Tc bone scintigraphy 243  
     Computed tomography (CT) 167  
     Magnetic resonance imaging (MRI) 62  
     Positron emission tomography (PET) 45  
     Conventional radiography 114  
Active oncotherapy   
     Primary lung cancer surgery 189  
     Chemotherapy 236  
     EGFR-TKI 17  
     EGFR-TKI + chemotherapy 9  
     Bisphosphonate treatment                    438  
          zoledronic acid 148  
          pamidronat 69  
          clodronat 166  
          lodronat  23  
          bisphosphonate not specified 32  
Co-morbidities    
     Hypertension 284  
     Diabetes mellitus 86  
     COPD 189  
 
Table 1. Clinicopathological characteristics of lung cancer patients with bone metastasis 
∗: In 61 cases, two different imaging techniques provided the diagnosis of bone metastasis 
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Co-morbidities Serum creatinine BUN Number of cases 
no co-morbidity 7.78% 15.56% 180 
only hypertension 11.81% 11.81% 144 
only diabetes 8.33% 25.00% 12 
only COPD 2.38% 7.14% 84 
hypertension + diabetes 12.20% 17.07% 41 
hypertension + COPD 8.33% 14.29% 72 
diabetes + COPD 14.29% 14.29% 7 
all co-morbidities 12.00% 16.00% 25 
 
Table 2. Ratio of patients in the pathological range (PRR) for serum creatinine and BUN for 
different co-morbidity groups at the time of lung cancer diagnosis (number of cases 
included) 
The “number of cases” column contains the number of patients in each group where renal 
function parameters are available. 
 
 
 
 
 
 All patients Males Females p-value 
Serum creatinine (median)     
     At the time of lung cancer diagnosis 75.0 µmol/l 81.0 µmol/l 68.0 µmol/l p<0.001 
     At the time of bone metastasis diagnosis 77.0 µmol/l 81.0 µmol/l 70.0 µmol/l p<0.001 
     Last available data      83.0 µmol/l 87.0 µmol/l 79.0 µmol/l p=0.001 
Blood urea nitrogen (BUN) (median)     
     At the time of lung cancer diagnosis 5.4 mmol/l 5.7 mmol/l 5.2 mmol/l p=0.001 
     At the time of metastasis bone diagnosis 6.0 mmol/l 6.4 mmol/l 5.7 mmol/l p=0.005 
     Last available data 7.6 mmol/l 8.2 mmol/l 7.1 mmol/l p=0.005 
 
Table 3. Laboratory parameters in lung cancer patients with bone metastasis (p-values 
indicate results of the Mann-Whitney U test for median comparison) 
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Figure titles and legends 
Figure 1. 
 
Figure 1. Changes in the ratio of cases in the pathological range (PRR) during the course of 
the disease.  
(A) Differences between initial values of PRR for serum creatinine between patient groups of 
hypertension versus no hypertension. (B) Differences of PRR and FR values for serum 
creatinine at the time of the bone metastasis. FR (failure rate) values represent the ratio of 
new pathological cases in the group (indicated with the patterned area), while PRR values 
depict the ratio of the total number of pathological cases in the group. (C) Differences of PRR 
and FR values for serum creatinine at the time of the last laboratory results. (D) Differences 
of initial values of PRR for BUN between patient groups of hypertension versus no 
hypertension.  (E) Differences of PRR and FR values for BUN at the time of bone metastasis. 
(F) Differences of PRR and FR values for BUN at the time of the last laboratory results.  
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Figure 2. 
 
Figure 2. Kaplan-Meier curves for patients who did not receive bisphosphonate and/or 
chemotherapy. 
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